Inhaled corticosteroids in COPD: The clinical evidence

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 525-537

  Ernst, Pierre ^a,b   Saad, Nathalie ^a   Suissa, Samy ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; PLACEBO; TRIAMCINOLONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ARTICLE; ASTHMA; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; MEDICAL HISTORY; ONSET AGE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SMOKING; SPUTUM; SURVIVAL; DRUG EFFECTS; EOSINOPHIL; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; EOSINOPHILS; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SPUTUM; TREATMENT OUTCOME;

EID: 84922147098     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00128914     Document Type: Article

References (151)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207.
3. Gershon AS, Wang C, Wilton AS, et al. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 2010;170:560-565.
4. Gershon AS, Guan J, Victor JC, et al. Quantifying health services use for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:596-601.
5. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773.
6. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-584.
7. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-825.
8. Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006;100:595-609.
9. Kiri VA, Pride NB, Soriano JB, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005;172:460-464.
10. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
11. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168:329-335.
12. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953.
13. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823.
14. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
15. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
16. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
17. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
18. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
19. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
20. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-128.
21. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842-846.
22. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
23. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149.
24. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-223.
25. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
26. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008;102:1099-1108.
27. Keene ON, Calverley PM, Jones PW, et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 2008;32:17-24.
28. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; CD002991.
29. Spencer S, Karner C, Cates CJ, et al. Inhaled corticosteroids versus long-acting (32-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; CD007033.
30. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007;356:2211-2212.
31. Kesten S, Plautz M, Piquette CA, et al. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 2007;30:898-906.
32. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011;5:44-49.
33. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Int Med 2007;146:545-555.
34. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:927-933.
35. Keene ON, Vestbo J, Anderson JA, et al. Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 2009;34:1018-1023.
36. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646.
37. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800.
38. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
39. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005;25:634-639.
40. Suissa S, Brassard P, Ernst P. Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. Am J Med 2003;115:377-381.
41. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-725.
42. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41:1017-1022.
43. Suissa S. Will SUMMIT reach the peak in COPD? Thorax 2014;69:405-407.
44. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting (32-agonist in one inhaler versus long-acting (32-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; CD006829.
45. Bousquet J. Inhaled corticosteroids in severe COPD. Lancet Respir Med 2013;1:177-178.
46. Halpin DM. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005;59:1187-1194.
47. Aaron SD, Fergusson DA. Exaggeration of treatment benefits using the "event-based" number needed to treat. CMAJ 2008;179:669-671.
48. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-329.
49. Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013;68:540-543.
50. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-1648.
51. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Int Med 2003;138:969-973.
52. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-941.
53. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-338.
54. Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J 2008;32:829-831.
55. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008;31:1274-1284.
56. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-351.
57. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
58. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166.
59. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
60. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416.
61. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229.
62. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-512.
63. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014;312:1114-1121.
64. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-719.
65. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-1036.
66. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306.
67. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in asthmatic patients taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183:589-595.
68. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; CD010115.
69. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010;36:751-757.
70. Singanayagam A, Chalmers JD, Akram AR, et al. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41.
71. Restrepo MI, Mortensen EM, Anzueto A. Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Eur Respir J 2011;38:1-3.
72. Brassard P, Suissa S, Kezouh A, et al. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-678.
73. Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-1113.
74. Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-262.
75. Ernst P, Dell'Aniello S, Mikaeloff Y, et al. Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. BMC Pulm Med 2011;11:59.
76. Buehring B, Viswanathan R, Binkley N, et al. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol 2013;132:1019-1030.
77. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003;114:10-14.
78. Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002;166:1563-1566.
79. Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008;38:1451-1458.
80. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83-88.
81. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699-708.
82. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002;54:59-64.
83. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-720.
84. O'Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012;106:1487-1493.
85. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009;122:472-478.
86. Faul JL, Wilson SR, Chu JW, et al. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 2009;7:14-20.
87. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001-1006.
88. Zimmerman B, Gold M, Wherrett D, et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate. J Allergy Clin Immunol 1998;101:425-426.
89. Todd GRC, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-461.
90. Drake AJ, Howells RJ, Shield JP, et al. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002;324:1081-1082.
91. Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavirboosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005;90:4394-4398.
92. Li AM. Ritonavir and fluticasone: beware of this potentially fatal combination. J Pediatr 2006;148:294-295.
93. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-266.
94. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006;61:405-408.
95. Lapi F, Kezouh A, Suissa S, et al. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J 2013;42:79-86.
96. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-336.
97. Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-966.
98. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
99. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539-543.
100. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 2001;12:229-234.
101. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-1174.
102. Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350:979-982.
103. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-727.
104. Gonzalez AV, Li G, Suissa S, et al. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther 2010;23:65-70.
105. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
106. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14:Suppl. B, 5B-32B.
107. Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996;153:1802-1811.
108. Celli BR, Halbert RJ, Nordyke RJ, et al. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005;118:1364-1372.
109. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-1689.
110. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875-1881.
111. Tai A, Tran H, Roberts M, et al. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014;69:805-810.
112. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750.
113. Postma DS, Brusselle G, Bush A, et al. I have taken my umbrella, so of course it does not rain. Thorax 2012;67:88-89.
114. Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010;40:62-67.
115. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf Date last updated: August 12, 2014.
116. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013;41:1252-1256.
117. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-963.
118. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012;67:701-708.
119. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-664.
120. Tan WC, Bourbeau J, Hernandez P, et al. Bronchodilator responsiveness and reported respiratory symptoms in an adult population. PLoS One 2013;8:e58932.
121. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-424.
122. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-879.
123. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-619.
124. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
125. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-1485.
126. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158:1511-1517.
127. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-198.
128. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-971.
129. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-913.
130. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-527.
131. Pavord ID, Gibson PG. Inflammometry: the current state of play. Thorax 2012;67:191-192.
132. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
133. Nair P. Update on clinical inflammometry for the management of airway diseases. Can Respir J 2013;20:117-120.
134. Maestrelli P. Same role and same treatment for airway eosinophilia in asthma and COPD? Eur Respir J 2007;29:831-833.
135. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.
136. Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014;44:789-791.
137. Malinovschi A, Janson C, Holmkvist T, et al. Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur Respir J 2006;28:339-345.
138. Corradi M, Majori M, Cacciani GC, et al. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax 1999;54:572-575.
139. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (Feno) for clinical applications. Am J Respir Crit Care Med 2011;184:602-615.
140. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J 2012;40:1098-1105.
141. Juusela M, Pallasaho P, Ronmark E, et al. Dose-dependent association of smoking and bronchial hyperresponsiveness. Eur Respir J 2013;42:1503-1512.
142. James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009;54:24-32.
143. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993;6:Suppl. 16, 53-83.
144. Yap E, Chua WM, Jayaram L, et al. Can we predict sputum eosinophilia from clinical assessment in patients referred to an adult asthma clinic? Int Med J 2013;43:46-52.
145. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34:812-818.
146. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-539.
147. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-437.
148. Travers J, Weatherall M, Fingleton J, et al. Towards individualised medicine for airways disease: identifying clinical phenotype groups. Eur Respir J 2012;39:1033-1034.
149. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209.
150. Wise RA, Anzueto A, Cotton D, et al. Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-1501.
151. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-1294.